Comparative Pharmacology
Head-to-head clinical analysis: NUCYNTA versus VICODIN ES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUCYNTA versus VICODIN ES.
NUCYNTA vs VICODIN ES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tapentadol is a centrally acting analgesic with dual mechanisms of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition.
Hydrocodone is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways.
50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg/day.
Oral: 1 tablet (7.5 mg hydrocodone/300 mg acetaminophen) every 4-6 hours as needed for pain; maximum 6 tablets per day due to acetaminophen limit.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 3-5 hours); no significant accumulation with repeated dosing at recommended intervals.
Hydrocodone: terminal half-life approximately 3.3-4.5 hours in adults, extended in hepatic or renal impairment. Acetaminophen: terminal half-life about 2-3 hours.
Primarily renal excretion (approximately 95% of the dose is excreted in urine as tapentadol and its conjugates; <1% excreted unchanged in feces).
Hydrocodone: primarily renal (urine) as unchanged drug and metabolites (O-demethylation and 6-keto-reduction products); ~26% excreted unchanged. Acetaminophen: renal (urine), ~85% as glucuronide and sulfate conjugates, ~2% unchanged.
Category C
Category C
Opioid Analgesic
Opioid Analgesic